	US 11,730,752 B2
	Use of NMN for the prevention and/or treatment of joint pain induced by physical activity, and corresponding compositions
Guillaume Bermond, Marseilles (FR); and Laurent Garcon, Sausset les Pins (FR)
Assigned to NUVAMID SA, Nyon (CH)
Appl. No. 17/791,092
Filed by NUVAMID SA, Nyon (CH)
PCT Filed Jan. 12, 2021, PCT No. PCT/EP2021/050499 § 371(c)(1), (2) Date Jul. 6, 2022, PCT Pub. No. WO2021/144274, PCT Pub. Date Jul. 22, 2021.
Claims priority of application No. FR2000270 (FR), filed on Jan. 13, 2020.
Prior Publication US 2023/0060438 A1, Mar. 2, 2023
Int. Cl. A01N 43/04 (2006.01); A61K 31/70 (2006.01); A61K 31/706 (2006.01); A61P 19/02 (2006.01); A61P 29/00 (2006.01); A61K 45/06 (2006.01)

CPC A61K 31/706 (2013.01) [A61K 45/06 (2013.01); A61P 19/02 (2018.01); A61P 29/00 (2018.01)]

15 Claims

1. A method of treatment of joint pain induced by physical activity, comprising topically administrating nicotinamide mononucleotide (NMN), a pharmaceutically acceptable derivative thereof, or a pharmaceutically acceptable salt thereof.